Taipei Exchange - Delayed Quote TWD

Chi Sheng Pharma & Biotech Co., Ltd (4111.TWO)

Compare
28.25
-0.25
(-0.88%)
At close: January 22 at 1:30:38 PM GMT+8
Currency in TWD All numbers in thousands
Breakdown
TTM
12/31/2022
12/31/2021
12/31/2020
Total Revenue
1,089,639.00
1,143,073.00
1,022,298.00
979,359.00
Cost of Revenue
718,531.00
720,565.00
665,719.00
656,435.00
Gross Profit
371,108.00
422,508.00
356,579.00
322,924.00
Operating Expense
287,877.00
268,676.00
237,520.00
247,362.00
Operating Income
83,231.00
153,832.00
119,059.00
75,562.00
Net Non Operating Interest Income Expense
9,998.00
-169.00
-676.00
1,571.00
Pretax Income
112,103.00
162,284.00
131,775.00
81,425.00
Tax Provision
-3,482.00
-16,998.00
24,079.00
22,284.00
Net Income Common Stockholders
115,493.00
154,006.00
80,751.00
59,141.00
Diluted NI Available to Com Stockholders
115,493.00
154,006.00
80,751.00
59,141.00
Basic EPS
2.02
2.70
1.42
1.04
Diluted EPS
2.02
2.69
1.41
1.03
Basic Average Shares
56,983.00
56,983.00
56,983.00
56,983.00
Diluted Average Shares
57,261.00
57,315.00
57,279.00
57,221.00
Total Expenses
1,006,408.00
989,241.00
903,239.00
903,797.00
Net Income from Continuing & Discontinued Operation
115,493.00
154,006.00
80,751.00
59,141.00
Normalized Income
115,443.40
179,279.60
107,698.45
59,147.54
Interest Income
11,367.00
1,356.00
417.00
1,733.00
Interest Expense
1,369.00
1,525.00
1,093.00
162.00
Net Interest Income
9,998.00
-169.00
-676.00
1,571.00
EBIT
113,472.00
163,809.00
132,868.00
81,587.00
EBITDA
175,169.00
236,686.00
211,944.00
165,729.00
Reconciled Cost of Revenue
718,531.00
720,565.00
665,719.00
656,435.00
Reconciled Depreciation
61,697.00
72,877.00
79,076.00
84,142.00
Net Income from Continuing Operation Net Minority Interest
115,585.00
179,282.00
107,696.00
59,141.00
Total Unusual Items Excluding Goodwill
177.00
3.00
-3.00
-9.00
Total Unusual Items
177.00
3.00
-3.00
-9.00
Normalized EBITDA
174,992.00
236,683.00
211,947.00
165,738.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
35.40
0.60
-0.55
-2.46
12/31/2020 - 12/31/2007

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers